Jaguar Health, a San Francisco-based pharmaceutical company with 49 employees, specializes in plant-derived medicines for gastrointestinal issues in humans and animals, including Mytesi for HIV patients and Canalevia-CA1 for dogs. The company went public on May 13, 2015, and operates through human and animal health segments.
Jonathan B Siegel bought 18,000 shares of JAGX on 31 March at $0.00 per share, worth a total of $0. They now own 9,000 JAGX shares, or a 200% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
